"Certolizumab Pegol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
| Descriptor ID |
D000068582
|
| MeSH Number(s) |
D05.750.741.125 D12.644.541.500.650.250 D12.776.124.486.485.114.224.060.500 D12.776.124.486.485.680.650.250 D12.776.124.790.651.114.224.060.500 D12.776.124.790.651.680.650.250 D12.776.377.715.548.114.224.200.500 D12.776.377.715.548.680.650.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Certolizumab Pegol".
- Chemicals and Drugs [D]
- Macromolecular Substances [D05]
- Polymers [D05.750]
- Polyethylene Glycols [D05.750.741]
- Certolizumab Pegol [D05.750.741.125]
- Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
- Peptide Fragments [D12.644.541]
- Immunoglobulin Fragments [D12.644.541.500]
- Immunoglobulin Fab Fragments [D12.644.541.500.650]
- Certolizumab Pegol [D12.644.541.500.650.250]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
- Immunoglobulin Fragments [D12.776.124.486.485.680]
- Immunoglobulin Fab Fragments [D12.776.124.486.485.680.650]
- Certolizumab Pegol [D12.776.124.486.485.680.650.250]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
- Immunoglobulin Fragments [D12.776.124.790.651.680]
- Immunoglobulin Fab Fragments [D12.776.124.790.651.680.650]
- Certolizumab Pegol [D12.776.124.790.651.680.650.250]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
- Immunoglobulin Fragments [D12.776.377.715.548.680]
- Immunoglobulin Fab Fragments [D12.776.377.715.548.680.650]
- Certolizumab Pegol [D12.776.377.715.548.680.650.250]
Below are MeSH descriptors whose meaning is more specific than "Certolizumab Pegol".
This graph shows the total number of publications written about "Certolizumab Pegol" by people in this website by year, and whether "Certolizumab Pegol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Certolizumab Pegol" by people in Profiles.
-
Dal?n J, Luttropp K, Svedbom A, Black CM, Kachroo S. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-a Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study. Adv Ther. 2020 09; 37(9):3746-3760.
-
Dal?n J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016 Jul; 36(7):987-95.
-
Chang MB, Sri JC, Driscoll M, Gaspari AA. Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers. J Drugs Dermatol. 2011 Aug; 10(8):914-6.